- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00724815
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (NP101-007)
February 2, 2016 updated by: NuPathe Inc.
The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study
This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours after patch activation.
Key secondary objectives included:
- The proportion of subjects who were nausea free at two hours after patch activation.
- The proportion of subjects who were photophobia free at two hours after patch activation.
- The proportion of subjects who were phonophobia free at two hours after patch activation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects stayed in the study until they had treated one migraine headache with a study patch or two months after randomization, whichever occurred first.
During a migraine headache, subjects rated their baseline headache pain severity in a Migraine Study Diary using a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) and applied the study patch only if their score was 2 or 3 (i.e., qualifying migraine headache).
In addition to headache pain severity, subjects also recorded the presence or absence of aura, nausea, phonophobia, and photophobia, as well as the location of their headache (unilateral or bilateral) and whether their headache increased with movement.
Study Type
Interventional
Enrollment (Actual)
530
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
-
California
-
Newport Beach, California, United States
-
San Francisco, California, United States
-
Santa Monica, California, United States
-
-
Connecticut
-
Fairfield, Connecticut, United States
-
-
Florida
-
Ocala, Florida, United States
-
Palm Beach Gardens, Florida, United States
-
Sunrise, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Columbus, Georgia, United States
-
Decatur, Georgia, United States
-
Savannah, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
Kalamazoo, Michigan, United States
-
-
Missouri
-
Springfield, Missouri, United States
-
St. Louis, Missouri, United States
-
-
New York
-
Mount Vernon, New York, United States
-
Plainview, New York, United States
-
-
North Carolina
-
Greensboro, North Carolina, United States
-
-
Ohio
-
West Chester, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
Wynnewood, Pennsylvania, United States
-
-
Tennessee
-
Memphis, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
San Antonio, Texas, United States
-
-
Virginia
-
Alexandria, Virginia, United States
-
Virginia Beach, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is an adult male or female, age range 18 years to 65 years.
- Subject has a diagnosis of migraine headache, with or without aura, as defined in the ICDH-II and the diagnosis was made before the age of 50.
- Subject typically experiences moderate to severe headaches during a migraine attack.
- Subject has at least a one year history of migraine.
- Subject will be judged to be in good health, based on results of a medical history, physical examination, vital signs, ECG and laboratory profile.
- Female subject of childbearing potential must have a negative pregnancy test at screening and prior to randomization.
- Subject must have a negative drug screen.
- Subject must be capable of reading and understanding either English or Spanish subject information materials. Be able to successfully apply a practice patch, carry-out all subject procedures, and be able to voluntarily sign and date an IRB approved IC agreement.
- Subject has an acceptable patch application site (upper arm) that is relatively hair free and has no scars, tattoos, scratches, or bruises.
Exclusion Criteria:
- Subject has or plans to start, stop, or change treatment or dose with prophylactic anti-migraine treatment within 3 months prior to the subjects' study randomization date and through the final visit.
- Subject has or plans to start, stop, or change treatment or dose of any of the following within 3 months prior to the subjects' study randomization date through final visit: anxiolytics, lithium and other mood stabilizers, hypnotics or antipsychotics.
- Subject had less than one migraine per month or more than six migraines per month, or more than 15 headache days per month for any of the three months prior to randomization.
- Subject has suspected or confirmed cardiovascular disease that contraindicates study participation.
- Subject has a history of epilepsy or conditions associated with a lowered seizure threshold.
- Subject has Raynaud's disease.
- Subject has a history of basilar or hemiplegic migraines.
- Subject has a current diagnosis of a major depressive disorder per the DSM IV R.
- Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or dependence.
- Subject is unwilling to discontinue use of serotonin agonists (triptans), except for the study patch, through the Final Visit.
- Subject has taken SSRI's, SNRI's, TCA's, MAOI's or preparations containing St. John's Wort within 1 month prior to screening and/or is planning to start any of these medications during the study.
- Subject is unwilling to discontinue use of a PD-5 inhibitors through the Final Visit.
- Subject has taken ergot medications within 7 days prior to Randomization and/or is unwilling to discontinue use through the Final Visit.
- Subject has a history of a significant allergy or hypersensitivity to any component of the study patch.
- Subject has any generalized skin irritation or disease including eczema, psoriasis, melanoma, or contact dermatitis.
- Subject has clinically significant abnormal laboratory parameters, vital signs or ECG parameters.
- Subject is known to be hepatitis B, hepatitis C or HIV positive.
- Subject has hepatic dysfunction based on laboratory results or if in the opinion of the Investigator the subject's history, physical examination or other laboratory tests suggest hepatic dysfunction.
- Female subject who is pregnant, breast feeding, or if of childbearing potential, is not using or is unwilling to use an effective form of contraception during the study and for a period of 30 days following dosing.
- Subject has known history of failure to respond to sumatriptan.
- Subject has participated in a clinical study within 30 days of screening or is planning to participate in another clinical study.
- Subject has been previously enrolled in NP101-007
- Subject is electrically sensitive or who have electrically sensitive support systems (e.g., pacemaker).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sumatriptan
NP101 - sumatriptan iontophoretic transdermal patch
|
Sumatriptan iontophoretic transdermal patch
Other Names:
|
Placebo Comparator: Placebo
Placebo iontophoretic transdermal patch
|
NP101 Placebo iontophoretic transdermal patch
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Free at Two Hours
Time Frame: 2 hours post patch activation
|
Subjects whose headache severity score equaled zero (0) two hours post patch activation and who had not received any rescue medication before their two-hour assessment.
|
2 hours post patch activation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Photophobia Free at Two Hours
Time Frame: 2 hours post patch activation
|
Subjects who were photophobia free and who had not received any rescue medication before their two-hour assessment.
|
2 hours post patch activation
|
Phonophobia Free at Two Hours
Time Frame: 2 hours post patch activation
|
Subjects who were phonophobia free and who had not received any rescue medication before their two-hour assessment.
|
2 hours post patch activation
|
Nausea Free at Two Hours
Time Frame: 2 hours post patch activation
|
Number of subjects who were nausea free and who had not received any rescue medication before their two-hour assessment.
|
2 hours post patch activation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Mark Pierce, MD, NuPathe Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
July 1, 2009
Study Completion (Actual)
July 1, 2009
Study Registration Dates
First Submitted
July 28, 2008
First Submitted That Met QC Criteria
July 29, 2008
First Posted (Estimate)
July 30, 2008
Study Record Updates
Last Update Posted (Estimate)
February 4, 2016
Last Update Submitted That Met QC Criteria
February 2, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Serotonin Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Vasoconstrictor Agents
- Sumatriptan
Other Study ID Numbers
- PROT-15-NP101-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Disorders
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
Vastra Gotaland RegionNot yet recruiting
Clinical Trials on NP101 - Sumatriptan iontophoretic transdermal patch
-
NuPathe Inc.CompletedMigraine DisordersUnited States
-
NuPathe Inc.Completed
-
NuPathe Inc.CompletedCompare Bioequivalence Patches Previously Used in the NP101-007 StudyUnited States
-
Alza Corporation, DE, USAWithdrawnPain, Postoperative | Pediatrics
-
Mundipharma Pte Ltd.Mundipharma Korea Ltd; Mundipharma (Hong Kong) Ltd; Mundipharma Distribution...CompletedOsteoarthritis | Rheumatoid Arthritis | Lower Back Pain | Joint Pain | Muscle PainHong Kong, Korea, Republic of, Philippines
-
Agile TherapeuticsCompleted
-
Cedars-Sinai Medical CenterTerminatedDehydration, Diverting Ileostomy, LoperamideUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
Vibe G Frøkjær, MD, PhDHvidovre University Hospital; Herlev HospitalRecruiting
-
Travanti Pharma Inc.ResearchPointCompletedLateral Epicondylitis | (Tennis Elbow)United States